News Abbott Laboratories

Stocks

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 16:02:00 2026-08-21 EDT			After hours 18:07:36
116.64 ^USD	+2.19%		115.50	-0.97%

08-21	Global markets live: Walmart, Nvidia, Ross Stores, SpaceX, Delta Air Lines…
08-21	TD Cowen Adjusts Price Target on Abbott Laboratories to $135 From $115, Maintains Buy Rating	MT

All News

Mentions Relevance

08-21	TD Cowen Adjusts Price Target on Abbott Laboratories to $135 From $115, Maintains Buy Rating	MT
08-20	Abbott to pay $670 million to settle some preterm infant formula cases	RE
08-20	Abbott Reaches $670 Million Settlement Over Infant Formula Claims	MT
08-20	Abbott to Pay $670 Million to Settle Baby-Formula Litigation	DJ
08-20	Abbott reaches agreements to resolve portion of litigation over infant formula	RE
08-20	Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants	PR
08-20	Abbott Laboratories Signs Supply, Distribution Deal With Avricore Health's HealthTab Unit	MT
08-20	Healthtab Ltd and Abbott Enter Multi-Year Collaboration Agreement for Point-Of-Care Testing Across the Uk	CI
08-17	Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare	PR
08-13	Citigroup Adjusts Price Target on Abbott Laboratories to $125 From $112, Maintains Buy Rating	MT
08-13	Wolfe Research Upgrades Abbott Laboratories to Outperform From Peer Perform, PT is $130	MT
08-12	Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis	PR
08-11	Abbott teams up with Google Health to improve Lingo
08-11	Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI	PR
08-11	Abbott and Google Launch First-of-its-Kind Partnership to Transform Everyday Health Through Glucose Insights and AI	CI
08-05	Abbott Laboratories Submits Notification of Production Activity to the Ftz Board	CI
07-28	Tranche Update on Abbott Laboratories's Equity Buyback Plan announced on October 16, 2024.	CI
07-28	UBS Adjusts Price Target on Abbott Laboratories to $125 From $135, Maintains Buy Rating	MT
07-28	Abbott Laboratories : initiates clinical study to show outcomes for real-world use of TriClip™ in repairing leaky tricuspid heart valve	PU
07-28	Rothschild & Co Redburn Adjusts PT on Abbott Laboratories to $119 From $126, Maintains Neutral Rating	MT
07-27	Freenome, Abbott Laboratories' Colorectal Cancer Screening Test Approved by FDA; Freenome Earns $100 Million Milestone Payment	MT
07-24	Abbott defeats shareholder lawsuit over 2022 infant formula recall	RE
07-24	Abbott wins dismissal of shareholder lawsuit over 2022 infant formula recall	RE
07-23	Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating	MT
07-22	Leerink Partners Adjusts Price Target on Abbott Laboratories to $109 From $106, Maintains Market Perform Rating	MT